August 30, 2016 10:01 PM ET

Pharmaceuticals

Company Overview of Nektar Therapeutics

Executive Profile

Lutz Lingnau

Independent Director and Chairman of Organization & Compensation Committee, Nektar Therapeutics
AgeTotal Calculated CompensationThis person is connected to 2 Board Members in 2 different organizations across 6 different industries.

See Board Relationships
73$344,136

Background

Mr. Lutz Lingnau is a Board Observer of Evestra, Inc. Mr. Lingnau served as the Chief Executive Officer and President of Schering Berlin, Inc. He held this position from 1989 to his retirement in 2005. He joined Schering AG's business trainee program in 1966. From 1968 to 1989, he served in various capacities at Schering AG and in a number of subsidiaries in South America and the United States, including as President of Berlex Laboratories, Inc., from 1983 to 1985, as ...

Corporate Headquarters

455 Mission Bay Boulevard South
San Francisco, California 94158

United States

Phone: 415-482-5300
Fax: 415-339-5300

Board Members Memberships

2007-Present
Independent Director and Chairman of Organization & Compensation Committee

Education

There is no Education data available.

Other Affiliations

Annual Compensation

There is no Annual Compensation data available.

Stocks Options

There is no Stock Options data available.

Total Compensation

Total Annual Cash Compensation$75,250
Total Calculated Compensation$344,136
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Michael W. Aguiar Chief Executive Officer, President, Director and Member of Stock Option Committee
Innoviva, Inc.
$721.4K
Peter M. Hecht Ph.D. Co-Founder, Chief Executive Officer and Director
Ironwood Pharmaceuticals, Inc.
$100.0K
James A. Schoeneck Chief Executive Officer, President and Director
Depomed, Inc.
$708.3K
Mark R. Baker J.D.Chief Executive Officer, Director and Member of Science Committee
Progenics Pharmaceuticals, Inc.
$597.1K
Peter S. Greenleaf Chairman and Chief Executive Officer
Sucampo Pharmaceuticals, Inc.
$565.3K
Compensation as of Fiscal Year 2015.

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Nektar Therapeutics, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.